@article{0e132961c56c4040a88b874c8d6563f3,
title = "Activity of EGFR TKIs in Caucasian Patients With NSCLC Harboring Potentially Sensitive Uncommon EGFR Mutations: Clinical Lung Cancer",
abstract = "Background: Molecular characterization of non–small-cell lung cancer (NSCLC), defined predictive and druggable mutations that greatly modified patient prognoses. The most frequent driver mutations detected in NSCLC are epidermal growth factor receptor (EGFR) mutations, accounting for approximately 90% of exon 19 deletions and exon 21 point mutations. The other EGFR mutations are classified as uncommon or nonclassical and include exon 18 point mutations, exon 20 insertions, and combined mutations, which present different sensitivity to tyrosine kinase inhibitor (TKI) targeting. Patients and Methods: We collected data from EGFR TKI-naive patients with metastatic NSCLC, harboring EGFR exon 18 mutations and EGFR combined mutations treated with first- or second-generation EGFR TKIs. Efficacy end points were evaluated considering the activity of EGFR TKIs in exon 18 versus double-mutation EGFR groups. Results: Eighty-eight patients harboring uncommon EGFR mutations were evaluated in our analysis, and subdivided into 2 group: complex mutations (cohort A = 46 patients) and double mutations in exon 18 (cohort B = 42 patients). The results showed a median progression-free survival of 8.3 versus 12.3 months (hazard ratio [HR], 0.65; P = .06) and a median overall survival of 17.0 versus 31.0 months (HR, 0.62, P = .04) favoring the EGFR combination group. Within the combination group, no detrimental effect was associated with exon 20 mutations. Conclusion: Our study confirmed that EGFR exon 18 and combination mutations might be considered potentially sensitive uncommon mutations, with a similar survival compared with the well known common EGFR mutations. Comparative analysis showed that patients with complex mutations achieved longer survival compared with the exon 18 group, without correlation with the presence of exon 20 mutations. {\textcopyright} 2018 Elsevier Inc. Uncommon epidermal growth factor receptor (EGFR) mutations reported in non–small-cell lung cancer, accounting approximately 10%-15% of all EGFR mutations, are a heterogeneous group characterized by different clusters: exon 20 insertion and mutations, exon 18 mutations, and complex mutations. Although available data confirming the intrinsic resistance of exon 20 insertions to EGFR tyrosine kinase inhibitors (TKIs) of first- and second-line generation, data about exon 18 and complex mutations are suggesting the activity of EGFR TKIs. In this clinical study, we showed exon 18 and EGFR complex mutations might be considered sensitive uncommon mutations, showing interesting survival results. {\textcopyright} 2018 Elsevier Inc.",
keywords = "Complex mutations, Exon 18, Exon 20, Lung cancer, Tyrosine kinase inhibitors, afatinib, epidermal growth factor receptor, erlotinib, gefitinib, antineoplastic agent, EGFR protein, human, protein kinase inhibitor, adult, aged, Article, cancer patient, cancer staging, cancer survival, Caucasian, clinical article, clinical outcome, clinical practice, comparative study, computer assisted tomography, controlled study, enzyme inhibition, exon, female, gene mutation, human, male, medical history, multicenter study, mutational analysis, non small cell lung cancer, observational study, outcome assessment, overall survival, point mutation, progression free survival, retrospective study, small cell lung cancer, smoking, treatment response, whole body PET, antagonists and inhibitors, genetics, lung tumor, middle aged, mortality, mutation, survival analysis, treatment outcome, very elderly, Adult, Aged, Aged, 80 and over, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, ErbB Receptors, Exons, Female, Humans, Lung Neoplasms, Male, Middle Aged, Mutation, Neoplasm Staging, Protein Kinase Inhibitors, Retrospective Studies, Survival Analysis, Treatment Outcome",
author = "A. Passaro and A. Prelaj and L. Bonanno and M. Tiseo and A. Tuzi and C. Proto and R. Chiari and D. Rocco and C. Genova and C. Sini and D. Cortinovis and S. Pilotto and L. Landi and C. Bennati and A. Camerini and L. Toschi and C. Putzu and G. Cerea and G. Spitaleri and F. Cappuzzo and {de Marinis}, F.",
note = "Cited By :8 Export Date: 28 February 2020 CODEN: CLCLC Correspondence Address: Passaro, A.; Division of Thoracic Oncology, European Institute of Oncology - IEO, Via G. Ripamonti, Italy; email: antonio.passaro@ieo.it Chemicals/CAS: afatinib, 439081-18-2, 850140-72-6, 850140-73-7; epidermal growth factor receptor, 79079-06-4; erlotinib, 183319-69-9, 183321-74-6; gefitinib, 184475-35-2, 184475-55-6, 184475-56-7; Antineoplastic Agents; EGFR protein, human; ErbB Receptors; Protein Kinase Inhibitors References: Herbst, R.S., Heymach, J.V., Lippman, S.M., Lung cancer (2008) N Engl J Med, 359, pp. 1367-1380; Pao, W., Miller, V., Zakowski, M., EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib (2004) Proc Natl Acad Sci U S A, 101, pp. 13306-13311; Paez, J.G., Janne, P.A., Lee, J.C., EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy (2004) Science, 304, pp. 1497-1500; Masserelli, E., Johnson, F.M., Erickson, H.S., Uncommon epidermal growth factor receptor mutations in non–small-cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance (2013) Lung Cancer, 80, pp. 235-241; Lynch, T.J., Bell, D.W., Sordella, R., Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib (2004) N Engl J Med, 350, pp. 2129-2139; Shi, Y., Au, J.S., Thongprasert, S., A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non–small-cell lung cancer of adenocarcinoma histology (PIONEER) (2014) J Thorac Oncol, 9, pp. 154-162; Rosell, R., Carcereny, E., Gervais, R., Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non–small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial (2012) Lancet Oncol, 13, pp. 239-246; Mok, T.S., Wu, Y.L., Thongprasert, S., Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma (2009) N Engl J Med, 361, pp. 947-957; Maemondo, M., Inoue, A., Kobayashi, K., Gefitinib or chemotherapy for non–small-cell lung cancer with mutated EGFR (2010) N Engl J Med, 362, pp. 2380-2388; Mitsudomi, T., Morita, S., Yatabe, Y., Gefitinib versus cisplatin plus docetaxel in patients with non–small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial (2010) Lancet Oncol, 11, pp. 121-128; Zhou, C., Wu, Y.L., Chen, G., Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non–small-cell lung cancer (OPTIMAL, CTONG-0802) (2015) Ann Oncol, 26, pp. 1877-1883; Sequist, L.V., Yang, J.C., Yamamoto, N., Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations (2013) J Clin Oncol, 31, pp. 3327-3334; Wu, Y.L., Zhou, C., Hu, C.P., Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non–small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial (2014) Lancet Oncol, 16, pp. 213-222; Wu, Y.L., Zhou, C., Liam, C.K., First-line erlotinib versus gemcitabine/cisplatin in patients with advanced EGFR mutation-positive non–small-cell lung cancer: analyses from the phase III, randomized, open-label, ENSURE study (2015) Ann Oncol, 26, pp. 1883-1889; Ettinger, D.S., Wood, D.E., Akerley, W.E., Non–small-cell lung cancer, version 6.2015 (2015) J Natl Compr Canc Netw, 13, pp. 515-524; Galli, C., Corrao, G., Imbimbo, M., Uncommon mutations in epidermal growth factor receptor and response to first and second generation tyrosine kinase inhibitors: a case series and literature review (2018) Lung Cancer, 115, pp. 135-142; O'Kane, G.M., Bradbury, P.A., Feld, R., Uncommon EGFR mutations in advanced non–small-cell lung cancer (2017) Lung Cancer, 109, pp. 137-144; Tu, H.Y., Ke, E.E., Yang, J.J., A comprehensive review of uncommon EGFR mutations in patients with non–small-cell lung cancer (2017) Lung Cancer, 114, pp. 96-102; Yang, J.C., Sequist, L.V., Geater, S.L., Clinical activity of afatinib in patients with advanced non–small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6 (2015) Lancet Oncol, 16, pp. 830-838; Planchard, D., Popat, S., Kerr, K., Metastatic non–small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2018) Ann Oncol, 29, pp. iv192-iv237; Chiu, C.H., Yang, C.H., Shih, C.T., Epidermal growth factor receptor tyrosine kinase inhibitor treatment response in advanced lung adenocarcinomas with G719X/L861Q/S768I mutations (2015) J Thorac Oncol, 10, pp. 793-799; Herbst, R.S., Review of epidermal growth factor receptor biology (2004) Int J Radiat Oncol Biol Phys, 59, pp. 21-26; Beau-Faller, M., Prim, N., Ruppert, A.M., Rare EGFR exon 18 and exon 20 mutations in non–small-cell lung cancer on 10 117 patients: a multicenter observational study by the French ERMETIC-IFCT network (2014) Ann Oncol, 25, pp. 126-131; Kobayashi, Y., Togashi, Y., Yatabe, Y., EGFR exon 18 mutations in lung cancer: molecular predictors of augmented sensitivity to afatinib or neratinib as compared with first- or third-generation TKIs (2015) Clin Cancer Res, 21, pp. 5305-5313; Keam, B., Kim, D.W., Park, J.H., Rare and complex mutations of epidermal growth factor receptor, and efficacy of tyrosine kinase inhibitor in patients with non–small-cell lung cancer (2014) Int J Clin Oncol, 19, pp. 594-600; Cheng, C., Wang, R., Li, Y., EGFR exon 18 mutations in east Asian patients with lung adenocarcinomas: a comprehensive investigation of prevalence, clinicopathologic characteristics and prognosis (2015) Sci Rep, 5, p. 3959; Wu, J.Y., Yu, C.J., Chang, Y.C., Effectiveness of tyrosine kinase inhibitors on “uncommon” epidermal growth factor receptor mutations of unknown clinical significance in non–small-cell lung cancer (2011) Clin Cancer Res, 17, pp. 3812-3821; Baek, J.H., Sun, J.M., Min, Y.J., Efficacy of EGFR tyrosine kinase inhibitors in patients with EGFR-mutated non–small-cell lung cancer except both exon 19 deletion and exon 21 L858R: a retrospective analysis in Korea (2015) Lung Cancer, 87, pp. 148-154; Wu, S.G., Chang, Y.L., Hsu, Y.C., Good response to gefitinib in lung adenocarcinoma of complex epidermal growth factor receptor (EGFR) mutations with the classical mutation pattern (2008) Oncologist, 12, pp. 1276-1284; Hata, A., Yoshioka, H., Fujita, S., Complex mutations in the epidermal growth factor receptor gene in non–small-cell lung cancer (2010) J Thorac Oncol, 5, pp. 1524-1528; Wells, A., EGF receptor (1999) Int J Biochem Cell Biol, 31, pp. 637-643; Klughammer, B., Brugger, W., Cappuzzo, F., Examining treatment outcomes with erlotinib in patients with advanced non–small-cell lung cancer whose tumors harbor uncommon EGFR mutations (2016) J Thorac Oncol, 11, pp. 545-555; Watanabe, S., Minegishi, Y., Yoshizawa, H., Effectiveness of gefitinib against non–small-cell lung cancer with the uncommon EGFR mutations G719X and L861Q (2014) J Thorac Oncol, 9, pp. 189-194; Pilotto, S., Rossi, A., Vaval{\`a}, T., Outcomes of first-generation EGFR-TKIs against non–small-cell lung cancer harboring uncommon EGFR mutations: a post hoc analysis of the BE-POSITIVE study (2018) Clin Lung Cancer, 19, pp. 93-104",
year = "2019",
doi = "10.1016/j.cllc.2018.11.005",
language = "English",
volume = "20",
pages = "e186--e194",
journal = "Clin. Lung Cancer",
issn = "1525-7304",
publisher = "Elsevier Inc.",
number = "2",
}